Anupam Rama
Stock Analyst at JP Morgan
(4.53)
# 288
Out of 5,182 analysts
309
Total ratings
52.06%
Success rate
23.65%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRAX First Tracks Biotherapeutics | Initiates: Overweight | $31 | $18.10 | +71.27% | 1 | Apr 23, 2026 | |
| REPL Replimune Group | Downgrades: Underweight | n/a | $2.68 | - | 13 | Apr 13, 2026 | |
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $37 → $41 | $40.95 | +0.12% | 20 | Apr 1, 2026 | |
| MAZE Maze Therapeutics | Maintains: Overweight | $52 → $58 | $26.47 | +119.12% | 3 | Mar 31, 2026 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $44 → $41 | $40.81 | +0.47% | 5 | Mar 25, 2026 | |
| SLDB Solid Biosciences | Maintains: Overweight | $11 → $12 | $7.50 | +60.00% | 10 | Mar 25, 2026 | |
| ZLAB Zai Lab | Maintains: Overweight | $39 → $32 | $21.88 | +46.25% | 14 | Mar 18, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $55 → $58 | $15.29 | +279.33% | 7 | Mar 18, 2026 | |
| ERAS Erasca | Maintains: Overweight | $24 → $25 | $19.15 | +30.55% | 2 | Mar 18, 2026 | |
| CTMX CytomX Therapeutics | Upgrades: Overweight | $7 → $12 | $4.29 | +179.72% | 4 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $177 | $128.04 | +38.24% | 22 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $74 | $23.99 | +208.46% | 4 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $89 → $94 | $74.52 | +26.14% | 13 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $45 | $21.00 | +114.29% | 12 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $11.32 | +182.69% | 1 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $96 | $37.28 | +157.51% | 12 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $67 | $36.61 | +83.04% | 9 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $40 | $14.12 | +183.29% | 2 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $147 → $145 | $104.04 | +39.37% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $7 → $6 | $8.07 | -25.65% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $20 | $10.19 | +96.27% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $13.26 | +28.25% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $14.49 | +31.12% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $44.11 | -45.59% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $29.48 | +167.98% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.44 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $20.98 | +14.39% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $66.59 | +20.14% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $43.61 | -8.28% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.86 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.78 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $6.10 | +113.11% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $4.99 | +4,910.02% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.71 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $61.60 | -5.84% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $16.81 | -28.61% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $10.64 | +247.74% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $98.51 | -44.17% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.25 | +270.73% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $24.43 | +121.04% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $2,250 | $4.51 | +49,789.14% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $18.04 | +49.67% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $308.51 | -55.59% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $7.97 | +502.26% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.61 | +1,763.35% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $69.22 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.04 | - | 2 | Jul 21, 2017 |
First Tracks Biotherapeutics
Apr 23, 2026
Initiates: Overweight
Price Target: $31
Current: $18.10
Upside: +71.27%
Replimune Group
Apr 13, 2026
Downgrades: Underweight
Price Target: n/a
Current: $2.68
Upside: -
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Neutral
Price Target: $37 → $41
Current: $40.95
Upside: +0.12%
Maze Therapeutics
Mar 31, 2026
Maintains: Overweight
Price Target: $52 → $58
Current: $26.47
Upside: +119.12%
Travere Therapeutics
Mar 25, 2026
Maintains: Overweight
Price Target: $44 → $41
Current: $40.81
Upside: +0.47%
Solid Biosciences
Mar 25, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $7.50
Upside: +60.00%
Zai Lab
Mar 18, 2026
Maintains: Overweight
Price Target: $39 → $32
Current: $21.88
Upside: +46.25%
Olema Pharmaceuticals
Mar 18, 2026
Maintains: Overweight
Price Target: $55 → $58
Current: $15.29
Upside: +279.33%
Erasca
Mar 18, 2026
Maintains: Overweight
Price Target: $24 → $25
Current: $19.15
Upside: +30.55%
CytomX Therapeutics
Mar 16, 2026
Upgrades: Overweight
Price Target: $7 → $12
Current: $4.29
Upside: +179.72%
Mar 12, 2026
Maintains: Overweight
Price Target: $176 → $177
Current: $128.04
Upside: +38.24%
Mar 12, 2026
Maintains: Overweight
Price Target: $120 → $74
Current: $23.99
Upside: +208.46%
Mar 10, 2026
Maintains: Overweight
Price Target: $89 → $94
Current: $74.52
Upside: +26.14%
Mar 9, 2026
Maintains: Overweight
Price Target: $33 → $45
Current: $21.00
Upside: +114.29%
Mar 3, 2026
Initiates: Overweight
Price Target: $32
Current: $11.32
Upside: +182.69%
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $37.28
Upside: +157.51%
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $36.61
Upside: +83.04%
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $14.12
Upside: +183.29%
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $104.04
Upside: +39.37%
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $8.07
Upside: -25.65%
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $10.19
Upside: +96.27%
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $13.26
Upside: +28.25%
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $14.49
Upside: +31.12%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $44.11
Upside: -45.59%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $29.48
Upside: +167.98%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.44
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $20.98
Upside: +14.39%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $66.59
Upside: +20.14%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $43.61
Upside: -8.28%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $1.86
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.78
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $6.10
Upside: +113.11%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $4.99
Upside: +4,910.02%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.71
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $61.60
Upside: -5.84%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $16.81
Upside: -28.61%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $10.64
Upside: +247.74%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $98.51
Upside: -44.17%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.25
Upside: +270.73%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $24.43
Upside: +121.04%
Jan 11, 2021
Initiates: Overweight
Price Target: $2,250
Current: $4.51
Upside: +49,789.14%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $18.04
Upside: +49.67%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $308.51
Upside: -55.59%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $7.97
Upside: +502.26%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.61
Upside: +1,763.35%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $69.22
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $4.04
Upside: -